Lucid Diagnostics Inc. (LUCD) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Stockholders held by Lucid Diagnostics Inc. on July 23, 2024. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in New York, New York. The filing details the ratification of corporate governance matters, capital structure amendments, and auditor appointments.
Key Financial Metrics
This filing is a current report regarding corporate events and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent Form 10-K or 10-Q for financial statements.
Material Changes and Corporate Actions
The following material actions were approved by stockholders representing approximately 84.6% of the shares outstanding:
- Board of Directors Election: Three Class C directors were re-elected for terms expiring at the third succeeding annual meeting:
- Lishan Aklog, M.D. (40,757,459 votes For)
- Debra J. White (43,874,470 votes For)
- Dennis A. Matheis (43,900,526 votes For)
- Capital Structure Amendment: Stockholders approved an amendment to the Certificate of Incorporation to increase the authorized common stock from 200,000,000 shares to 300,000,000 shares. The amendment was filed with the Delaware Secretary of State and became effective on July 23, 2024.
- Preferred Stock Issuance Approval: Stockholders approved the issuance of common stock upon conversion of Series B and Series B-1 Convertible Preferred Stock sold in private offerings in March and May 2024, satisfying Nasdaq Listing Rule 5635 requirements.
- Auditor Ratification: Marcum LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Guidance, Outlook, and Risks
The filing does not provide management commentary on future financial guidance, operational outlook, or specific risk factors. The document references the Definitive Proxy Statement (filed June 6, 2024) for a fuller description of the preferred stock offerings and the certificate amendment.
Key Facts for Investor Verification
- Verify the effective date of the Certificate of Amendment (July 23, 2024) to confirm the new authorized share count of 300,000,000.
- Review the terms of the Series B and Series B-1 Convertible Preferred Stock in the 8-K filings dated March 14, 2024, and May 7, 2024, to understand potential dilution.
- Confirm the composition of the Board of Directors, noting the staggered terms for Class A (expiring 2025) and Class B (expiring 2026) directors.
- Check the most recent quarterly or annual report for financial health metrics, as this 8-K contains no financial data.